Adrian Rawcliffe's most recent trade in Wave Life Sciences Ltd. was a trade of 76,200 Share Option (right to buy) done . Disclosure was reported to the exchange on Aug. 11, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Wave Life Sciences Ltd. | Adrian Rawcliffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2025 | 76,200 | 76,200 | - | - | Share Option (right to buy) | |
| Wave Life Sciences Ltd. | Adrian Rawcliffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2025 | 12,700 | 28,815 (0%) | 0% | 0 | Ordinary Shares | |
| Adaptimmune Therapeutics Plc | Adrian Rawcliffe | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 5,143,248 | 5,143,248 | - | - | Option to purchase Ordinary Shares | |
| Adaptimmune Therapeutics Plc | Adrian Rawcliffe | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 3,428,832 | 3,428,832 | - | - | Option to purchase Ordinary Shares | |
| Adaptimmune Therapeutics Plc | Adrian Rawcliffe | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 0.58 per share. | 17 Jan 2025 | 30,601 | 44,327 (0%) | 0% | 0.6 | 17,773 | American Depositary Shares representing Ordinary Shares |
| Adaptimmune Therapeutics Plc | Adrian Rawcliffe | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 0.57 per share. | 13 Jan 2025 | 29,096 | 41,582 (0%) | 0% | 0.6 | 16,724 | American Depositary Shares representing Ordinary Shares |
| Adaptimmune Therapeutics Plc | Adrian Rawcliffe | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 0.59 per share. | 13 Jan 2025 | 17,934 | 25,711 (0%) | 0% | 0.6 | 10,543 | American Depositary Shares representing Ordinary Shares |
| Adaptimmune Therapeutics Plc | Adrian Rawcliffe | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 0.59 per share. | 13 Jan 2025 | 12,539 | 17,801 (0%) | 0% | 0.6 | 7,372 | American Depositary Shares representing Ordinary Shares |
| Wave Life Sciences Ltd. | Adrian Rawcliffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 32,230 | 32,230 | - | - | Share Option (right to buy) | |
| Wave Life Sciences Ltd. | Adrian Rawcliffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 16,115 | 16,115 (0%) | 0% | 0 | Ordinary Shares | |
| Adaptimmune Therapeutics Plc | Adrian Rawcliffe | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 0.67 per share. | 16 Jan 2024 | 30,080 | 44,848 (0%) | 0% | 0.7 | 20,244 | American Depositary Shares representing Ordinary Shares |
| Adaptimmune Therapeutics Plc | Adrian Rawcliffe | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 0.79 per share. | 16 Jan 2024 | 9,304 | 14,104 (0%) | 0% | 0.8 | 7,350 | American Depositary Shares representing Ordinary Shares |
| Adaptimmune Therapeutics Plc | Adrian Rawcliffe | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2024 | 7,633,296 | 7,633,296 | - | - | Option to purchase Ordinary Shares | |
| Adaptimmune Therapeutics Plc | Adrian Rawcliffe | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2024 | 1,696,272 | 1,696,272 | - | - | Option to purchase Ordinary Shares | |
| Adaptimmune Therapeutics Plc | Adrian Rawcliffe | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 0.85 per share. | 11 Jan 2024 | 17,257 | 26,388 (0%) | 0% | 0.9 | 14,739 | American Depositary Shares representing Ordinary Shares |
| Adaptimmune Therapeutics Plc | Adrian Rawcliffe | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 0.84 per share. | 11 Jan 2024 | 11,945 | 18,395 (0%) | 0% | 0.8 | 9,994 | American Depositary Shares representing Ordinary Shares |
| Wave Life Sciences Ltd. | Adrian Rawcliffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2023 | 45,000 | 45,000 | - | - | Share Option (right to buy) | |
| Wave Life Sciences Ltd. | Adrian Rawcliffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 21,000 | 21,000 | - | - | Share Option (right to buy) | |
| Wave Life Sciences Ltd. | Adrian Rawcliffe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2021 | 42,000 | 42,000 | - | - | Share Option (right to buy) |